U.S. FDA Long-Term Globalization Strategy Under Development
This article was originally published in PharmAsia News
Executive Summary
Coping with an increasingly global device and drug industry will require a paradigm shift that relies less on U.S. FDA's own staff and more on data and resource sharing with other countries, the agency says